ROR1 and triple-negative breast carcinoma: A phase 1 trial by Specht et al. (2018) tested autologous CAR-T cells directed against ROR1 for patients with ROR1-positive triple-negative breast cancer or NSCLC and observed a mixed response among the two NSCLC patients [122].